We are live on ! Find out more
MPM BioImpact

MPM BioImpact Portfolio holdings

AUM $1.35B Turnover 42.55%
1-Year Est. Return 172.14%
 

MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.

This Fund
S&P 500
This Quarter Est. Return
+11.01%
1 Year Est. Return
+172.14%
3 Year Est. Return
+619.29%
5 Year Est. Return
+756.25%
10 Year Est. Return
–
AUM
$385M
AUM Growth
-$540K
Cap. Flow
+$13.4M
Cap. Flow %
3.48%
Top 10 Hldgs %
70.32%
Holding
34
New
1
Increased
10
Reduced
11
Closed
3
Avg Time Held
1.3 years
Top 10 Avg Time Held
1.1 years
Top 20 Avg Time Held
1 year

Top Sells

Rank Stock Value
1
QURE icon
uniQure
QURE
+$12.4M
2
HRMY icon
Harmony Biosciences
HRMY
+$7.68M
3
GTHX icon
G1 Therapeutics
GTHX
+$3.53M
4
INBX icon
Inhibrx
INBX
+$2.19M
5
PRAX icon
Praxis Precision Medicines
PRAX
+$1.45M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
CGEM icon
1
Cullinan Therapeutics
CGEM
$577M
$78.2M 20.33%
7,648,268
– –
2021 Q1
8 quarters
PRVB
2
DELISTED
Provention Bio
PRVB
$28.3M 7.35%
1,173,809
+275,326
+31% +$3.46M
2022 Q2
3 quarters
ISEE
3
DELISTED
IVERIC bio
ISEE
$25.4M 6.61%
1,045,691
-13,997
-1% -$306K
2022 Q3
2 quarters
ITOS icon
4
DELISTED
iTeos Therapeutics
ITOS
$23.8M 6.17%
1,745,943
– –
2020 Q3
10 quarters
INBX icon
5
DELISTED
Inhibrx
INBX
$22.5M 5.85%
1,192,281
-94,154
-7% -$2.19M
2022 Q2
3 quarters
NTLA icon
6
Intellia Therapeutics
NTLA
$1.4B
$21.3M 5.54%
572,459
+117,221
+26% +$4.6M
2021 Q3
6 quarters
RLAY icon
7
Relay Therapeutics
RLAY
$3.56B
$20.2M 5.24%
+1,225,634
New +$22M
2023 Q1
0 quarters
GERN icon
8
Geron
GERN
$561M
$18.2M 4.74%
8,401,565
-65,416
-0.8% -$186K
2021 Q3
6 quarters
RETA
9
DELISTED
Reata Pharmaceuticals
RETA
$16.5M 4.3%
176,874
-17,307
-9% -$1.02M
2022 Q1
4 quarters
RPTX icon
10
DELISTED
Repare Therapeutics
RPTX
$16.1M 4.19%
1,639,849
– –
2020 Q2
11 quarters
IOVA icon
11
Iovance Biotherapeutics
IOVA
$3.19B
$16M 4.15%
2,614,977
+465,427
+22% +$3.21M
2022 Q2
3 quarters
RGNX icon
12
Regenxbio
RGNX
$473M
$11.7M 3.03%
617,671
-3,701
-0.6% -$81.9K
2022 Q3
2 quarters
VERV icon
13
DELISTED
Verve Therapeutics
VERV
$11.6M 3.01%
803,501
-5,160
-0.6% -$101K
2022 Q3
2 quarters
MDGL icon
14
Madrigal Pharmaceuticals
MDGL
$8.81B
$8.73M 2.27%
36,038
+9,265
+35% +$2.52M
2022 Q2
3 quarters
TVTX icon
15
Travere Therapeutics
TVTX
$4.51B
$7.05M 1.83%
313,642
+31,931
+11% +$679K
2021 Q3
6 quarters
QURE icon
16
uniQure
QURE
$1.36B
$7.01M 1.82%
348,224
-591,742
-63% -$12.4M
2022 Q4
1 quarter
INSM icon
17
Insmed
INSM
$31B
$6.81M 1.77%
399,192
-11,271
-3% -$219K
2022 Q4
1 quarter
HOWL icon
18
Werewolf Therapeutics
HOWL
$46M
$6.21M 1.61%
2,388,011
– –
2021 Q2
7 quarters
CRNX icon
19
DELISTED
Crinetics Pharmaceuticals
CRNX
$5.79M 1.5%
360,392
-11,247
-3% -$208K
2021 Q3
6 quarters
RVMD icon
20
Revolution Medicines
RVMD
$34.9B
$5.35M 1.39%
247,022
+97,979
+66% +$2.41M
2021 Q3
6 quarters
TCRR
21
DELISTED
TCR2 Therapeutics
TCRR
$5.06M 1.31%
3,370,982
– –
2019 Q4
13 quarters
KDNY
22
DELISTED
Chinook Therapeutics
KDNY
$4.58M 1.19%
197,806
+117,806
+147% +$2.81M
2022 Q4
1 quarter
AXSM icon
23
Axsome Therapeutics
AXSM
$6.8B
$4.34M 1.13%
70,402
+18,427
+35% +$1.21M
2022 Q4
1 quarter
FOLD icon
24
DELISTED
Amicus Therapeutics
FOLD
$4.31M 1.12%
388,292
-12,118
-3% -$149K
2021 Q3
6 quarters
ARQT icon
25
Arcutis Biotherapeutics
ARQT
$3.33B
$2.8M 0.73%
254,137
-7,932
-3% -$115K
2022 Q1
4 quarters

Similar funds

MPM BioImpact's Q1 2023 Portfolio in Review

As of Q1 2023, MPM BioImpact held 34 positions worth $385M, down 0.14% from $385M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

MPM BioImpact deployed $13.4M of net new capital in Q1 2023, opening 1 new position and adding to 10 existing holdings. Its largest new stake was Relay Therapeutics: 1,225,634 shares worth $20.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was uniQure, an estimated $12.4M trimmed.

  • MPM BioImpact's largest Q1 2023 buy was Relay Therapeutics: 1,225,634 shares worth $20.2M.
  • MPM BioImpact added most to Intellia Therapeutics in Q1 2023, an estimated $4.6M increase.
  • MPM BioImpact's biggest Q1 2023 reduction was uniQure, cutting an estimated $12.4M.
  • MPM BioImpact fully exited Harmony Biosciences in Q1 2023, selling an estimated $7.68M.
  • MPM BioImpact's ten largest holdings make up 70% of its $385M portfolio in Q1 2023.
  • MPM BioImpact opened 1 new position and closed 3 in Q1 2023.
  • MPM BioImpact's portfolio value fell 0.14% quarter-over-quarter to $385M.

Based on MPM BioImpact's 13F filing for Q1 2023, filed 12 May 2023.